about
New recombinant vaccines based on the use of prokaryotic antigen-display systems.Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes.Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2.DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequencesImpact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.A macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgelsImproved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine.DNA vaccination.Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120.Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunizationDNA vaccines against human immunodeficiency virus type 1 in the past decade.A call for replicating vector prime-protein boost strategies in HIV vaccine design.T cell vaccines for microbial infections.Cloning of HBsAg-encoded genes in different vectors and their expression in eukaryotic cells.Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challengeUse of viral vectors for the development of vaccines.The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteersHighly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge.DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimensNovel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.Human immunodeficiency virus-1 vaccine design: where do we go now?New therapeutic vaccination strategies for the treatment of chronic hepatitis B.A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responsesTherapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck.Prime boost vaccines power up in people.HIV: viral blitzkrieg.Vaccines against epidemic and pandemic influenzaRecruiting London gay men into an HIV vaccine trial: Is it feasible?
P2860
Q33210092-18AB8A99-40AE-46AE-B6B6-402172E7B9A3Q33520582-D23916EA-0887-4C34-9642-D0E486540155Q33717525-D207C460-B55B-42CC-8402-53960265F8F8Q33737811-7CCB08D2-8B64-405B-8933-7D76430449D7Q33843297-789EB1C1-FC9F-4189-A48A-8B3F30706AF8Q33883887-CACD459E-B6D9-4F80-B817-323CC5BCB0D0Q34099087-88CAFEC9-CC59-423D-AC64-B11FAB846ED9Q34296144-7737354B-376F-464D-8B6E-F36D5FB57EFEQ34348561-1B84B76E-9B04-47EA-881C-375FE1BB0425Q34981649-03F707D8-52A3-4B06-9914-BD4404743EE4Q35155380-7C063E11-182C-4DEF-9062-7A7A30015D05Q35193454-9FFC3096-C44C-461A-AE77-A139EA9198DAQ35581126-645557E9-4AC4-4072-A1C2-291E0C36AAC3Q35623329-CB9A73F1-F096-431D-BAF5-A860172AFC28Q35635412-C6A3E5EA-9BDB-496D-8774-4FA988508E0AQ35745831-97EB7846-18A8-4203-B242-EE2D839AEEB1Q35851801-760D4F0C-27AF-4770-A9FE-780F979E6244Q36090185-F1495C8A-D51B-494D-AF9A-9D65703038D1Q36178495-51496E2A-63E7-40D0-959E-17006CCC3F72Q36473515-C4CBA95E-A329-426C-8A0A-54E00588B9EFQ36473694-CD82F2C2-6751-4B2F-9ABD-C74491C8130AQ36538907-F37E2044-7341-422E-9266-6BF3F2CB2070Q36780156-F78D3C97-A471-4DDF-B624-01A95D6ADC81Q36945335-F81886D2-3DB6-4858-B9D6-68FE825B88B7Q37094160-FB62546F-CC99-430C-8267-682E4C2A34A5Q37141704-22F4FE32-C46E-40EC-A909-DA6942FE43F8Q37181874-50A356BE-0488-4F0F-9D67-FF9EC1A45126Q37263878-E0352AC8-DA43-4039-BAF2-8F0D62462E69Q37399747-479363EC-1F26-4D19-9140-5A627B564428Q37801269-CF6D1BA3-D481-4CF2-8AF6-00A308DE78D9Q38180981-B9F30017-34F9-4E41-9B1C-20CA3F868730Q39906552-CACAB0BE-CE92-441A-9D04-696328A3C350Q41218508-BEDCD2D8-AC2F-43AE-B20F-5B8D2B0A49C0Q47929753-A08ED390-4262-4F26-BFA3-86DD68C9D67AQ51992509-E936932D-4BA2-4B0B-9DCF-6AB8E8B80141Q56550815-B81B0D2B-4B99-4831-9316-61E5B1840059Q57715912-5DFB156F-1F85-4FA8-951F-410367357FA6
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
New hope for an AIDS vaccine.
@ast
New hope for an AIDS vaccine.
@en
New hope for an AIDS vaccine.
@nl
type
label
New hope for an AIDS vaccine.
@ast
New hope for an AIDS vaccine.
@en
New hope for an AIDS vaccine.
@nl
prefLabel
New hope for an AIDS vaccine.
@ast
New hope for an AIDS vaccine.
@en
New hope for an AIDS vaccine.
@nl
P2860
P356
P1476
New hope for an AIDS vaccine.
@en
P2093
Harriet L Robinson
P2860
P304
P356
10.1038/NRI776
P577
2002-04-01T00:00:00Z